CVL-865

DRUG2 trials

Sponsors

AbbVie

Conditions

Seizures

Phase 2

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

CompletedNCT04244175

Start: 2020-01-27End: 2024-05-21Updated: 2025-05-30

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

TerminatedNCT04686786

Start: 2020-12-08End: 2024-12-05Updated: 2025-12-11

Related Papers

Medicines for Anxiety: A Hundred Years of Tranquillity and More to Come?

Human Psychopharmacology Clinical and Experimental2026-02-20

Pronounced antiseizure activity of the subtype‐selective <scp>GABA<sub>A</sub></scp> positive allosteric modulator darigabat in a mouse model of drug‐resistant focal epilepsy

CNS Neuroscience & Therapeutics2022-08-1414 citations

Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5‐Subtype Selective GABA<sub>A</sub>‐Positive Allosteric Modulator PF‐06372865 in Healthy Volunteers

Clinical Pharmacology in Drug Development2021-01-198 citations